Targeting angiogenesis in advanced cervical cancer

Targeting angiogenesis in advanced cervical cancer

Blog Article

Patients with advanced stage or recurrent cervical cancer represent a population with limited chemotherapeutic options.More specifically, JASMINE PEARLS patients with recurrent disease have a poor salvage rate, with a 5-year survival rate of less than 10%.This year, the first prospective phase III clinical trial exploring the anti-angiogenic agent, bevacizumab, was published, meeting its primary endpoint, with a significant improvement in overall Moisturizers survival.As such, a review of anti-angiogenic therapy in the treatment of this disease is warranted.